NBDF is excited to inform U.S.-based clinicians of new live and virtual educational opportunities from overseas! This coming fall, our friends at the Irish Haemophilia Society (IHS) will be offering a series of medical-based webinars that speak to key topics relevant to the care of patients with inherited bleeding disorders.
While the IHS Clinical Webinar Series is focused on clinicians and healthcare workers, patient leaders are also welcome to attend. The six webinars will be held on Zoom during the months of September, October, and November. Each webinar has a unique registration.
The program will include the following activities:
September 4th
Update on Haemophilia A and B
Speaker: Professor Niamh O'Connell, Director, National Coagulation Centre (NCC), St. James's Hospital, Dublin 8
September 11th
Update on Gene Therapy for Inherited Bleeding Disorders
Speaker: Dr. Radoslaw Kaczmarek, Assistant Research Professor of Pediatrics, Gene and Cell Therapy Laboratory, Indiana University School of Medicin
October 16th
Women and Bleeding Disorders
Speaker: Dr. Michelle Lavin, Consultant Haematologist, National Coagulation Centre, St. James's Hospital, Dublin. Chair, WFH WBD committee
October 30th
Update on Novel Therapies
Speaker: Professor Flora Peyvandi, Director, Angelo Bianco Bonomi Haemophilia and Thrombosis Centre, Milan.
November 20th
Update on von Willebrands Disease
Speaker Professor James O'Donnell, Consultant Haematologist, National Coagulation Centre , St. James's Hospital, Dublin. Director Institute of Vascular Biology, Royal College of Surgeons, Ireland
November 27th
Future of Paediatric Care for Children with Inherited Bleeding Disorders
Speaker: Dr. Beatrice Nolan, Director, Paediatric Haemophilia Comprehensive Care Centre, Children's Hospital Ireland, Crumlin, Dublin
Visit the series homepage to learn more and to register for these activities.
Please note that all webinars will start at 18.00 Irish time/1pm Eastern Standard Time.
The IHS Clinical Webinar Series is supported by an unrestricted educational grant from Novo Nordisk.
